FDA Proposes New Reporting Rules For Investigational Drugs

Federal regulators are proposing a new rule which would require investigational drug manufacturers to give an annual report on the progress of patients who have chosen to take the risk of trying their new, unapproved medications.

The FDA published a proposed rule, the Annual Summary Reporting Requirements Under The Right to Try Act, on July 23, which the agency says will provide more oversight on experimental drugs which address serious illnesses.

The Right to Try Act was passed in 2017, and allows patients facing life-threatening diseases or conditions who have no other options to volunteer to take experimental drugs, which have not yet been approved by the FDA. It is separate from those patients who participate in investigational clinical trials, since they do not need to be part of any trial to take the drug.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

However, with clinical trial subjects, the data is supposedly available to federal regulators, who can call for a halt to a clinical trial if too many patients are being seriously injured or dying. With Right to Try patients, there is no such reporting mechanism since they are not part of any clinical trial.

The new rule, if finalized, would create a statutory requirement that sponsors and manufacturers of investigational drugs submit an annual report which includes data on the progress of patients trying their unapproved drugs; much in the way that a clinical trial would provide that information.

According to the proposed rule, as published in the Federal Register this morning:

“The manufacturer or sponsor of an eligible investigational drug shall submit to FDA an annual summary of any use of such drug supplied under section 561B of the FD&C Act. Per the statute, the summary shall include the number of doses supplied, the number of patients treated, the use for which the drug was made available, and any known serious adverse events from use of the drug.”

“The FDA is dedicated to achieving the goals that Congress set forth in the Right to Try Act, so that patients facing terminal conditions have another avenue to access investigational medicines,” Dr. Anand Shah, Deputy Commissioner for Medical and Scientific Affairs, said in an FDA press release. “Today’s proposed rule builds on the FDA’s long-standing dedication to enhancing access for patients who are facing life-threatening diseases or conditions and our continued commitment to transparency.”

The FDA is taking public comment on the proposed rule until September 22, 2020. Comments can be submitted electronically at https://www.regulations.gov


Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Master Baby Food Lawsuit Filed in MDL Outlines How Toxic Metals Caused Autism, ADHD in Children
Master Baby Food Lawsuit Filed in MDL Outlines How Toxic Metals Caused Autism, ADHD in Children (Posted today)

Plaintiffs have submitted a baby food lawsuit Master Complaint that is expected to streamline the filing of lawsuits alleging that toxic heavy metals in Beech-Nut, Gerber, Hain and Nurture products caused ADHD, autism and other developmental disorders.

Lawsuit Claims AGGA Device Damaged Teeth, Resulting in Disfiguring Injury
Lawsuit Claims AGGA Device Damaged Teeth, Resulting in Disfiguring Injury (Posted today)

Another AGGA device lawsuit has been filed by a man who says he had to have the device surgically removed less than a year after having it implanted due to jaw problems and migraines.